Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Mattel Children's Hospital UCLA — Los Angeles, California
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- UCLA University of California Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- University of California Irvine — Orange, California
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in California: - University of California, San Diego — La Jolla, California
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- St. Joseph Hospital — Orange, California
- University of California, San Francisco — San Francisco, California
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in California: - University of Southern California — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Stanford Cancer Institute — Palo Alto, California
- University of California — San Francisco, California
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in California: - Kaiser Permanente — Los Angeles, California
- UCLA — Los Angeles, California
- Sutter Health - California Pacific Medical Center — San Francisco, California
- University of California, San Francisco — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in California: - Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in California: - Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Epic Care-Dublin — Dublin, California
- Bay Area Breast Surgeons Inc — Emeryville, California
- Epic Care Partners in Cancer Care — Emeryville, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Keck Medicine of USC Koreatown — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in California: - Precision NextGen Oncology & Research Center — Beverly Hills, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- University of California Los Angeles Rheumatology — Westwood, Los Angeles, California
Phase 2 Recruiting Academic/Other
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in California: - UCSF Benioff Children's Hospital Oakland — Oakland, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- Rady Children's Hospital — San Diego, California
- Stanford University — Stanford, California
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in California: - The Angeles clinic - A cedars SINAI AFFILIATE — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, San Francisco (UCSF) — San Francisco, California
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- University of California, San Diego / Rady Children's Hospital, San Diego — San Diego, California
- University of California, San Francisco — San Francisco, California
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in California: - City of Hope — Duarte, California
- HOAG — Newport Beach, California
- UCSF — San Francisco, California
Phase 2 Recruiting Network
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in California: - City of Hope - Duarte Cancer Center — Duarte, California
- UCLA Health Bowyer Oncology Center — Los Angeles, California
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology — San Francisco, California
- Stanford University Medical Center - Neurology — Stanford, California
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in California: - University of California, Irvine — Irvine, California
- University of California Los Angeles — Los Angeles, California
- University of California at San Francisco — San Francisco, California
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in California: - UCSF Benioff Children's Hospital — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in California: - Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in California: - Providence Medical Foundation — Fullerton, California
- California Research Institute — Los Angeles, California
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in California: - Lucille Packard Children's Hospital Stanford — Palo Alto, California
Phase 1, Phase 2 Recruiting Academic/Other
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate …
Sponsor: University of California, San Francisco
NCT ID: NCT06504381
Sites in California: - University of Southern California — Los Angeles, California
- University of California, San Diego — San Diego, California
- University of California — San Francisco, California
Phase 2 Recruiting Academic/Other
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Sponsor: Duke University
NCT ID: NCT06069726
Sites in California: - University of California, San Francisco — San Francisco, California